Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NIHARIKA B METTU

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1447427737
CMS profile
916702
Location
DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$84.58

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $50.00 1
Food and Beverage $34.58 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Ipsen Biopharmaceuticals, Inc $50.00 1
Genentech, Inc. $34.58 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NIHARIKA B METTU

NPI 1447427737 · CMS profile ID 916702

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447427737?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NIHARIKA B METTU, NPI 1447427737, CMS profile ID 916702. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447427737?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). NIHARIKA B METTU, NPI 1447427737, CMS profile ID 916702. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447427737?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
NIHARIKA B METTU, NPI 1447427737, CMS profile ID 916702, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1447427737?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $84.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ipsen Biopharmaceuticals, Inc $50.0011/05/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640616935 CMS
Genentech, Inc. $34.5801/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681160939 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $84.58 2
PY2022 $144.15 1
PY2023 $404.87 2
PY2025 $118.86 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $412,481.43 29
PY2024 Principal investigator $438,364.30 16
PY2023 Recipient $1,900.00 1
PY2023 Principal investigator $221,978.88 12
PY2022 Recipient $940.00 1
PY2022 Principal investigator $540,890.16 21
PY2021 Principal investigator $466,508.69 60
PY2020 Principal investigator $671,262.43 162
PY2019 Principal investigator $961,160.26 152

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $71.37 12/31/2022 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 914603053
Principal investigator 1 Merck Sharp & Dohme LLC $43,214.64 12/31/2022 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 940416923
Principal investigator 1 Merck Sharp & Dohme LLC $33,188.12 12/31/2022 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 940417013
Principal investigator 1 Merck Sharp & Dohme LLC $7,545.36 12/31/2022 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 940417069
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,887.36 12/08/2022 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER NEUROSURGERY
An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements No dispute reported 06/30/2026 924017721
Principal investigator 1 Merck Sharp & Dohme LLC $47,279.10 11/16/2022 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 940417011
Recipient PFIZER INC. $940.00 11/16/2022 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 949727869
Principal investigator 1 Genentech, Inc. $250,124.33 11/09/2022 Non-covered Recipient Entity
MAYO CLINIC
BACCI No dispute reported 06/30/2026 950637773
Principal investigator 1 Incyte Corporation $2,295.00 10/07/2022 Non-covered Recipient Entity
DUKE UNIVERSITY
A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK 3475) plus INCB Combinations in Advanced Solid Tumors No dispute reported 06/30/2026 905224165
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,477.16 10/05/2022 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER NEUROSURGERY
An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements No dispute reported 06/30/2026 924017723
Principal investigator 1 Incyte Corporation $7,745.00 09/28/2022 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905224159
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,651.44 08/19/2022 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER NEUROSURGERY
An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements No dispute reported 06/30/2026 924018125
Principal investigator 1 Incyte Corporation $17.79 07/11/2022 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905224161
Principal investigator 1 Incyte Corporation $53.37 07/11/2022 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905224163
Principal investigator 1 Incyte Corporation $297.00 06/29/2022 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905224155
Principal investigator 1 Incyte Corporation $39,471.30 06/07/2022 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1/2, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 905224157
Principal investigator 1 Genentech, Inc. $3,600.00 05/19/2022 Non-covered Recipient Entity
MAYO CLINIC
BACCI No dispute reported 06/30/2026 950661647
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,991.86 03/31/2022 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 914599383
Principal investigator 1 Incyte Corporation $57.46 03/09/2022 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905224151
Principal investigator 1 Incyte Corporation $2,105.00 03/09/2022 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905224153
Principal investigator 1 PFIZER INC. $79,062.50 03/02/2022 Non-covered Recipient Entity
American Association for Cancer Research AACR
REALWORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG BRCA MUTATION POSITIVE ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949698599
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,755.00 01/27/2022 Non-covered Recipient Entity
Duke Comp Cancer Cnt
Phase IIB TMB High Pan Tumor FA for tTMB - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) No dispute reported 06/30/2026 933192711